Apr. 4 at 9:06 AM
$ERAS has been crushing it relative to ImmunityBio lately — and the market has shown it. Over the most recent quarter,
$IBRX did rally hard, but Erasca actually outpaced it with bigger gains, showing serious momentum in its oncology pipeline and early Phase results driving the move.
And if you look at broader biotech returns, ERAS ranks ahead of IBRX on year-to-date performance, with stronger percentage gains vs ImmunityBio’s rally.
That doesn’t mean ImmunityBio doesn’t have a story — it does — but in pure recent performance and breakout strength,
$ERAS has been the more explosive ticker, and that’s why some traders are calling it the better biotech play right now.
